Shikari® Omalizumab ELISA Kit

$1,315.00

The Shikari® Omalizumab ELISA Kit is intended for the quantitative determination of omalizumab in serum and plasma. The Shikari® Omalizumab ELISA Kit is for Research Use Only and not for diagnostic procedures.

Omalizumab is a recombinant, humanized monoclonal antibody that targets immunoglobulin E (IgE), playing a key role in the treatment of allergic diseases such as moderate-to-severe asthma and chronic idiopathic urticaria. By binding to circulating IgE and preventing its interaction with high-affinity IgE receptors on mast cells and basophils, omalizumab reduces the release of proinflammatory mediators that contribute to the allergic cascade. This inhibition diminishes the activation and recruitment of inflammatory cells, including B-lymphocytes, T-lymphocytes, eosinophils, and fibroblasts, thereby modulating airway inflammation and remodeling.

In research and clinical settings, omalizumab serves as both a therapeutic and a monitoring target in immunology and allergy-focused studies. It is particularly valuable in therapeutic drug monitoring (TDM) applications, where maintaining optimal serum concentrations can improve clinical outcomes and reduce adverse effects. TDM of omalizumab allows clinicians to assess treatment efficacy, detect patient noncompliance, and monitor for the development of anti-drug antibodies (ADAs) that may impact drug pharmacokinetics and safety.

Omalizumab’s mechanism of action and its immunogenic potential make it a critical biomarker for understanding immune modulation in allergic diseases. Due to its recombinant protein structure and potential to elicit ADAs, omalizumab also represents a model biologic for biosimilar development and immunogenicity profiling. Its utility in precision medicine continues to expand, supporting individualized dosing regimens and contributing to broader biologic drug safety evaluations.

This product is manufactured in Turkey by Matriks Biotek.

Size 1 x 96 Well
Sensitivity 10 ng/mL
Dynamic Range 1000-30 ng/mL
Incubation Time 70 minutes
Sample Type Serum, Plasma
Immunogen
Source Species
Specificity
Expression System
Clone
Group
Alpha Chain
Beta Chain
Peptide
Peptide Source
Format
Buffer
Concentration
Storage 2-8°C
Alternative Names Omalizumab, anti-IgE monoclonal antibody, recombinant humanized IgG1 anti-IgE, anti-IgE biologic therapy, IgE-targeting monoclonal antibody, Xolair, IgE-neutralizing antibody, anti-allergy monoclonal antibody, anti-IgE recombinant therapeutic, mast cell IgE-blocking antibody.
Instructions For Use https://eaglebio.com/wp-content/uploads/2025/06/OMA-FD-XOL-shikari-omalizumab-elisa-instructions-for-use.pdf
MSDS https://eaglebio.com/wp-content/uploads/2025/06/OMA-FD-XOL-shikari-omalizumab-elisa-safety-data-sheet-sds.pdf

Product Citations